SELLING OFFER

Seek co-innovation with global enterprises and governmental institutions

Early Diagnosis Platform for Lung Cancer

243 2023. 4. 25.
Early Diagnosis Platform for Lung Cancer

Summary

Population-based screening of stage 0–I lung cancer is crucial to save lives. We describe the development of a method for the detection of a CYFRA 21-1-autoantibody complex and CYFRA 21-1 in plasma samples. The CIC/CYFRA 21-1 ratio allows the detection of stage I–IV lung cancer with 75.0% sensitivity and 97.3% specificity. 

Advantages and Innovations

  • Can be used in combination with LDCT for lung cancer screening;
  • Improve the diagnostic capacity of LDCT and reduce the false-positive rates;
  • StageⅠ lung cancer detection rate dramatically increases;
  • Improve the currently low 5-year survival rate.
     

Stage of Development

TRL 7 - Concept Stage

Description

Lung cancer is the most common cause of cancer-related deaths globally. Patients diagnosed at early-stage (0–I) have a higher survival rate than the metastasized stages (III–IV). Thus, there is great potential to reduce mortality by diagnosing lung cancer at stage 0~I through community screening. LDCT is a promising method, but it has a high false-positive rate. Therefore, a biomarker test that can be used in combination with LDCT for lung cancer screening to reduce false-positive rates is highly awaited. The present study evaluated the applicability of our lung cancer product to detect stage 0~IV lung cancer. our lung cancer product detects stage I, stage II, stage III, and stage IV cancers with the sensitivities of 77.5%, 78.1%, 67.4%, and 33.3%, respectively, at the specificity of 97.3%. These results indicate that our lung cancer product can be used in conjunction with LDCT to screen lung cancer.

 

  • Early Diagnosis of Breast Cancer (Phase 0~2, w/ Blood);
  • Lateral Flow Assay (4 Biomarkers Immunology test);
  • Sensitivity & Specificity: 78% & 90%;
  • Package: 48 tests/kit (Usage for 12 persons);
  • Run Time: 1 hour, KR Patent.

Technology Keywords

Market Application Keywords

2.7.12 Medical/health
4.1.3 Medical genetic engineering applications
5 MEDICAL/HEALTH RELATED
5.3 Other Medical/Health Related
5.3.6 Other medical/health related (not elsewhere classified)

Sector Group

Proximity & Social Economy and Health

Type and Size of Client

Industry SME 11-49

Type and Role of Partner Sought

  • Big sales company capable of selling lung cancer products
  • Sales companies capable of selling LDT (Lab Development Test)
  • A primary hospital that diagnoses lung cancer

Type of Partnership Considered

Joint Venture Agreement
License Agreement
Services Agreement

Company

Biometrix Technology Co., Ltd.

Internal Reference

BO20230004

Category

BO

If interested, please press this button.
We will answer you soon.

Filter